Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection
-
- E. S. Gray
- AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
-
- P. L. Moore
- AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
-
- I. A. Choge
- AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
-
- J. M. Decker
- University of Alabama at Birmingham, Birmingham, Alabama 35294
-
- F. Bibollet-Ruche
- University of Alabama at Birmingham, Birmingham, Alabama 35294
-
- H. Li
- University of Alabama at Birmingham, Birmingham, Alabama 35294
-
- N. Leseka
- AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
-
- F. Treurnicht
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
-
- K. Mlisana
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa
-
- G. M. Shaw
- University of Alabama at Birmingham, Birmingham, Alabama 35294
-
- S. S. Abdool Karim
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa
-
- C. Williamson
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
-
- L. Morris
- AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
書誌事項
- 公開日
- 2007-06-15
- 権利情報
-
- https://journals.asm.org/non-commercial-tdm-license
- DOI
-
- 10.1128/jvi.00239-07
- 公開者
- American Society for Microbiology
この論文をさがす
説明
<jats:title>ABSTRACT</jats:title> <jats:p>The study of the evolution and specificities of neutralizing antibodies during the course of human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of possible targets for vaccine design. In this study, we assessed the autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Our data show that potent but relatively strain-specific neutralizing antibodies develop within 3 to 12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies. However, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth. These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection.</jats:p>
収録刊行物
-
- Journal of Virology
-
Journal of Virology 81 (12), 6187-6196, 2007-06-15
American Society for Microbiology
